Here are nine highlights from the second quarter of 2017:
1. The company reported total revenue of $24.4 million.
2. U.S. commercial business total revenue was $21.9 million.
3. The company’s total operating expenses were $16.5 million, a decrease of $3.7 million from the first quarter of 2017.
4. Alphatec’s cash balance was $19.1 million, as of June 30.
5. The company saw an operating loss of $0.7 million, reflecting a sequential improvement from $3.4 million in the first quarter.
6. Non-GAAP adjusted EBITDA was $1.2 million.
7. Alphatec reported a U.S. commercial gross margin of 71 percent.
8. As of June 30, the company’s cash and cash equivalents were $19.1 million.
9. The sales from dedicated sales agents and distributors increased to more than 18 percent of U.S. commercial revenue.
In the second quarter, Alphatec received a patent for its uniplanar and monoaxial screws within its arsenal deformity line. The company also received a patent protecting the Alphatec Squadron Lateral Retractor.
More articles on devices:
Tissue Regenix acquires CellRight Technologies in $30M deal: 6 things to know
Study: Are physical exams of SI joint accurate for diagnoses?
Lane Hale named President & CEO of ECA Medical Instruments
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
